Lutathera (lutetium Lu 177 dotatate) - Novartis
Efficacy and safety of 177Lu-DOTATATE in advanced neuroendocrine neoplasms: a single-center retrospective study (ESMO Asia 2026) - Oct 1, 2026 - Abstract #365P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available 
Metastases • Retrospective data • Endocrine Cancer • Neuroendocrine Neoplasm • Oncology • Solid Tumor
https://cslide.ctimeetingtech.com/asia2026/attendee/confcal/print/presentation/1069
 
Akihiro Okada; Hiroshi Imaoka; Kanae Inoue; TOMONAO TAIRA; Tomoyuki Satake; Taro Shibuki; Mitsuhito Sasaki; Go Sawai; Kazuya Kanaya; Hiroumi Akita; Masataka Amisaki; Hideaki Takahashi; Shuichi Mitsunaga; Saori Mishima; Kohei Shitara; Masafumi Ikeda
 
Oct 1, 2026
 
Prev Next